Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. MUPHORAN (fotémustine)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

MUPHORAN (fotémustine)

Medicine - Posted on Feb 14 2019 - Updated on Jun 12 2019
Active substance (DCI)
  • fotémustine
history (3)
  • 6/27/18

    MUPHORAN (fotemustine), nitrosourea

    Moderate clinical benefit in the alternative treatment of advanced stage melanoma, following resistance to immunotherapies a...
    CAV :
    54321
    icône flèche
  • 7/9/14

    MUPHORAN

    -
    CAV :
    54321
    icône flèche
  • 2/1/06

    MUPHORAN, poudre et solution pour usage parentéral à diluer (perfusion) 1 flacon en verre brun de 208 mg - 1 ampoule(s) en verre de 4 ml : 331 870-2

    MUPHORAN, poudre et solution pour usage parentéral à diluer (perfusion) 1 flacon en verre brun de 208 mg - 1 ampoule(s) en verre de 4 ml : 331 870-2
    icône flèche
Technical information
ATC code
  • L01AD05
Manufacturer
SERVIER
Presentation

MUPHORAN, poudre et solution pour usage parentéral à diluer (perfusion) (code CIS : 63675185)
1 flacon(s) en verre brun de 208 mg - 1 ampoule(s) en verre de 4 ml - Code CIP : 34009 331 870 2 6

All our publications
    Drug therapy Nervous system cancers Skin and connective tissue cancers

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
aKPPJYm0M029Q1JN